Sunday, July 12, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
ENERGYUSDA's Revamped Biorefinery Loan Guarantee Program Is a Quiet Tailwind for ADM and Renewable Chemical ProducerstodayTECHThe AI Diffusion Rule Is Picking Winners Inside the Chip Stack — and It Is Not Who You Think4 weeks agoHEALTHCARE & FDATrump's Proposed Medicare Drug Savings Rule Puts PBMs in the Crosshairs — and Gives Pharma a Mixed SignaltodayENERGYThe FERC Docket Nobody Reads: How Pipeline Certificates Quietly Pick LNG's Winners4 weeks agoCRYPTOThe SEC's 2026 Crypto Regulatory Agenda Is a Green Light for Coinbase and RobinhoodtodayTECHThe HBM Monopoly: How Federal Memory Standards Lock In Micron4 weeks agoMARKETSFTC Forces John Deere to Open Its Repair Tools — Farmers Win, Deere's Software Moat Takes a HittodayTECHThe Tariff Arbitrage: How Chip Import Duties Reshape the Foundry Map4 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers — Vertex and CRISPR Therapeutics Just Doubled Their Addressable MarkettodayENERGYWhy Williams (WMB) Is Really a Policy Stock, Not a Pipeline Stock4 weeks agoTECHThe White House's $2 Billion Quantum Bet Has Clear Stock-Market Winners — and a Cryptography Deadline That Helps OtherstodayENERGYDOE Reopens the LNG Export Spigot: Cheniere Cashes In First, Kinder Morgan Collects the Toll4 weeks agoDEFENSENATO's Spending Surge Is Real and Getting Enforced — RTX, Lockheed, and AeroVironment Are the Direct BeneficiariestodayTECHThe Chip Stack Below the Pentagon's AI Buildup4 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts the Clock for SMR DeveloperstodayDEFENSEHII's Mission Technologies: The Unsexy Segment Where Navy Autonomy Dollars Actually Land First4 weeks agoENERGYCommonwealth LNG Permit Moves Forward — Cheniere and ConocoPhillips Are Watching CloselytodayTECHThe CHIPS Act Subsidy Ladder: Who Actually Receives the $39 Billion4 weeks agoTRADE & TARIFFSDeepSeek's Custom Chip Gambit Is a Direct Threat to Nvidia's China Revenue — and a Warning for AMDtodayDEFENSEThe Refueling Line Nobody Prices Into BWXT4 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts Years Off the SMR TimelineyesterdayDEFENSEThe Law That Guarantees Matson a Buyer, No Matter the Price4 weeks agoTECHTrump Accelerates Post-Quantum Encryption Deadlines — and a Handful of Small-Cap Security Firms Are the Direct BeneficiariesyesterdayENERGYThe Grid Hardening Bill Trade: How Federal Transmission Investment Lifts the Equipment Makers4 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers — Vertex and CRISPR Therapeutics Just Doubled Their Addressable MarketyesterdayTECHThe Export Control Squeeze: BIS Chip Rules Are Splitting the AI Hardware Market in Two4 weeks agoHEALTHCARE & FDAMedicare Starts Covering Obesity Drugs — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential CustomersyesterdayDEFENSEWho Loses if the Navy's 355-Ship Goal Quietly Becomes a 'Right-Sized Fleet' Retreat4 weeks agoTRADE & TARIFFSTariff Tailwinds Are Still Running for U.S. Metals — but the Easy Money in Steel and Aluminum May Already Be PricedyesterdayENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom4 weeks agoTRADE & TARIFFSMcCormick's $28M Tariff Refund Is a One-Time Cushion — the Underlying Cost Pressure Hasn't Gone AwayyesterdayDEFENSEMatson and the Jones Act: The Shipping Monopoly Washington Refuses to Touch4 weeks agoENERGYCommonwealth LNG Permit Review Opens — Another Export Terminal in the Queue Benefits the Whole LNG Supply ChainyesterdayDEFENSEThe Real Winner Behind the Navy's Shipbuilding "Get Well" Plan Is Second-Tier Suppliers, Not the Primes4 weeks agoMARKETSFTC Forces John Deere to Open Its Repair Ecosystem — and the Aftermarket Parts Industry WinsyesterdayDEFENSELeidos: The Non-Obvious Beneficiary of Navy Digital and Sustainment Modernization4 weeks agoDEFENSENATO's 3.5% GDP Spending Push Is a Multi-Year Order Book for U.S. Defense PrimesyesterdayENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear4 weeks agoCRYPTOSEC's Pending Crypto Safe Harbor Rule Is the Clearest Regulatory Tailwind Coinbase Has Seen in Years2 days agoENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch4 weeks agoHEALTHCARE & FDAMedicare Covering Obesity Drugs for the First Time Is a Direct Volume Catalyst for Novo Nordisk and Eli Lilly2 days agoDEFENSEAUKUS Pillar I Is a Slow-Burn Catalyst for GD and HII, Not a Pop3 weeks agoDEFENSENATO's 3.5% GDP Spending Push Sends a Long-Term Revenue Signal to Raytheon, Lockheed, and Northrop2 days agoENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade3 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Market2 days agoDEFENSEWhy BWXT Is Really a Policy Stock, Not an Industrial One3 weeks agoENERGYCommonwealth LNG Permit Review Opens a New Export Capacity Race — Cheniere Holds the Pole Position2 days agoDEFENSEHII vs. General Dynamics: Who Wins the Submarine Industrial Base Money3 weeks agoHEALTHCARE & FDAElevance Suing CMS Over Medicare Advantage Stars Is a Warning Sign for the Entire Managed Care Sector2 days agoENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactors3 weeks agoTECHWhite House Quantum Summit and Accelerated PQC Deadlines Create a Spending Runway for IonQ and IBM2 days agoENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centrus3 weeks agoHEALTHCARE & FDAMedicare Starts Covering GLP-1 Obesity Drugs — Novo Nordisk and Eli Lilly Are the Direct Winners5 days agoDEFENSEPalantir's Real Moat Is the Data Rights Clause, Not the AI3 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger Market5 days agoENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alive3 weeks agoDEFENSENATO's 'Report Card' Pressure Means Years of European Defense Spending — RTX and Lockheed Are the First Calls5 days agoDEFENSEElbit's America Problem: What Buy American Rules Really Do to a Foreign Prime3 weeks agoCRYPTOSEC Commissioner Signals Crypto Clarity Act Could Pass This Summer — Coinbase and Robinhood Are the Clearest Beneficiaries5 days agoDEFENSECounter-Drone Spending Is the Quiet Twin of Drone Spending3 weeks agoENERGYU.S.-Iran Initial Deal Eases Sanctions Pressure — Oil Prices Face a Ceiling, E&P Stocks Feel It5 days agoENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hub3 weeks agoTECHWhite House Lifts Export Controls on Anthropic's Advanced AI Models — Nvidia and AMD Are the Coattail Trade5 days agoDEFENSELeidos: The Losing Trade When "Efficiency" Becomes the Watchword in Washington3 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track Program as State-Level Momentum Builds — Constellation, Vistra, and Oklo Are the Plays5 days agoENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economics3 weeks agoDEFENSEThe US-Iran Ceasefire Deal Pressures Oil Prices — and Reshuffles the Defense Trade6 days agoENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deduction3 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Children as Young as 2, Widening the Market for Vertex and CRISPR Therapeutics6 days agoDEFENSEThe Space-Based ISR Land Grab Nobody's Pricing In: Rocket Lab's Vertical Integration Bet3 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Payday for AeroVironment6 days agoDEFENSEWho Actually Builds the Targets: The Overlooked Business Inside Kratos3 weeks agoCRYPTOCrypto Clarity Act Progress and SEC's ETF Rule Review Are the Two Biggest Near-Term Catalysts for Coinbase and Robinhood6 days agoENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keys3 weeks agoDEFENSENATO's Spending Surge Is Real — and the US Defense Primes Are the Ones Getting Paid6 days agoDEFENSEAxon Is a Homeland-Security Policy Stock Wearing a Police-Gear Disguise3 weeks agoTECHTrump's Quantum Computing Executive Orders Create a Policy Tailwind for a Handful of Public Names6 days agoDEFENSEGolden Dome Is a Sensor and Software Story Before It's a Missile Story3 weeks agoHEALTHCARE & FDAFDA's BHT and ADA Reassessment Puts Food Additive Users on Notice — and Creates an Opening for Clean-Label Supplierslast weekENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Gift3 weeks agoTRADE & TARIFFSNike's Tariff Refund Windfall Shows How Import-Heavy Brands Can Turn Trade Policy Into a Margin Storylast weekENERGYThe BLM Calendar That Moves COP and OXY3 weeks agoTECHTrump's Post-Quantum Cryptography Executive Order Creates a Compliance Spending Mandate — and Clear Beneficiarieslast weekDEFENSEMercury Systems: The Toll Booth Every Drone and Missile Program Has to Pass Through2 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Marketlast weekDEFENSEKratos vs. AeroVironment: Which One Actually Wins the Cheap-Drone-Swarm Pivot2 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironmentlast weekENERGYLNG Export Licenses: How a FERC Approval Mints a Monopoly2 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track Program, Adding Momentum to the SMR Buildout Tradelast weekDEFENSERTX's Two-Front Bet: Why Iran Tensions and NATO's 5% Pledge Hit the Same Ticker Differently2 weeks agoCRYPTOBitcoin Is Down 33% at Mid-Year and ETF Outflows Hit $4.3B in June — Coinbase and the Miners Are Feeling Itlast weekENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oil2 weeks agoENERGYWashington Is Rewriting Nuclear Radiation Safety Rules — Constellation, Vistra, and the SMR Crowd All Winlast weekDEFENSEChina's Rare-Earth Squeeze Will Hit Defense Primes Unevenly2 weeks agoENERGYThe US-Iran Initial Deal Puts Sanction Relief on the Table — and That's a Headwind for Oil Prices and E&P Stockslast weekDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primes2 weeks agoTRADE & TARIFFSNike's Tariff Refunds Are a One-Time Boost, Not a Structural Fix — Here's What the Q4 Beat Actually Meanslast weekDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Program2 weeks agoDEFENSEHegseth's NATO Broadside and European Force Review Put Defense Primes in a Complicated Spotlast weekDEFENSELeidos Is the Quiet Beneficiary of Every "Modernize Federal IT" Executive Order2 weeks agoTECHCommerce Department's AI Model Export Controls Are the Next Nvidia Headwind — and AMD Isn't Immunelast weekDEFENSESole-Source vs. Full-and-Open: The Slow Bleed in LMT's F-35 Sustainment Machine2 weeks agoHEALTHCARE & FDAMedicare Is Now Covering Wegovy — Novo Nordisk and Eli Lilly Just Got a Massive New Payerlast weekDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own It2 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Toddlers — Vertex and CRISPR Therapeutics Just Got a Bigger Marketlast weekDEFENSEThe Loser Nobody Names: Export Controls Squeeze Boeing From Both Sides2 weeks agoWHITE HOUSETrump's Quantum Executive Order Sets a Hard Deadline — and Quantum Computing Stocks Are the Immediate Beneficiarylast weekDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Streamlast weekDEFENSEHegseth's NATO Broadside and Europe Force Review Signal a Shift That Benefits U.S. Primes — at Europe's Expenselast weekDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligationlast weekHEALTHCARE & FDAMedicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customerslast weekDEFENSEWho Actually Cashes In on 'Golden Dome': The Subcontractor Layer Behind LMT and RTXlast weekCRYPTOBitcoin ETF Outflows Hit $4.3 Billion in June — Coinbase, MARA, and Strategy Are Carrying the Most Risklast weekDEFENSEHII Is a Congressional Appropriations Bet, Not a Navy Betlast weekDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment — and Pressure on Its Rivalslast weekDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Tradelast weekWHITE HOUSETrump's Quantum Executive Orders Set a 2030 Deadline — and a Spending Clock for IonQ, Rigetti, and the Cybersecurity Stacklast weekDEFENSEThe FMS Loophole: How State Department Sign-Offs Insulate Defense Primes From Shutdown Risklast weekENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is Movinglast weekDEFENSESentinel vs. Columbia: The Nuclear Triad's Budget Is a Zero-Sum Gamelast weekDEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets Paidlast weekDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In Spendinglast weekHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger Marketlast weekTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic Producerslast weekDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending Boomlast weekMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More Politicallast weekTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real Moneylast weekTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to Watchlast weekMARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big Techlast weekDEFENSEWhy L3Harris Is Really a Policy Stock, Not a Hardware Stocklast weekWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet Tailwindlast weekDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company Foreverlast week
1 free article left this week. A free account gets you 4 a week.Go Pro →
Healthcare & FDA

FDA Clears Casgevy for Toddlers — Vertex and CRISPR Therapeutics Just Doubled Their Addressable Market

Expanding the gene therapy's label to patients as young as 2 opens a new revenue layer for both companies.

Image: Money Racket
By at Money Racket · Jul 12, 2026

The FDA granted supplemental approval for Casgevy (exagamglogene autotemcel) in patients aged 2 and older with sickle cell disease or transfusion-dependent beta thalassemia. Previously, the therapy was only approved for patients 12 and up.

Who cashes in: Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) co-own Casgevy and split economics on every treatment. Pediatric patients represent a meaningful expansion of the eligible population — sickle cell disease disproportionately affects children, and catching patients earlier in disease progression is the clinical and commercial argument for the label extension. At a list price north of $2 million per treatment, even a handful of additional annual patients moves the revenue needle for CRSP, which is the smaller and more leveraged of the two. VRTX is a larger company with a diversified pipeline, so the incremental impact is real but not transformational at the stock level. Bluebird Bio (BLUE) also has an approved gene therapy for sickle cell (Lyfgenia), and this approval puts more competitive pressure on its already-thin commercial ramp.

At over $2 million per treatment, even a modest expansion of the eligible pediatric population is a direct revenue event for CRSP.

Who's exposed: Bluebird Bio (BLUE) is the most direct loser. Its Lyfgenia therapy competes in the same rare-disease space, and Casgevy's label now covers a younger population. Bluebird has struggled commercially and financially; a broader Casgevy label tightens the window for it to establish market share. Traditional standard-of-care players — hydroxyurea manufacturers and chronic transfusion programs — face long-term volume pressure as gene therapy access expands, though that shift plays out over years, not quarters.

What to watch next: The commercial tell is how many treatment centers are certified and staffed to handle pediatric gene therapy cases — the bottleneck has never been the label, it's been manufacturing slots and qualified sites. Watch VRTX and CRSP quarterly disclosures for the number of patients in the commercial funnel under age 12.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →